- Details
- Svetlana Avulova, MD, Urologic Oncology Fellow at Mayo Clinic received the 2021 BCAN New Discoveries Young Investigator Award for Patient-Centered Research. In this conversation with Ashish Kamat, MD she highlights her project titled “Sexual Function in Women Undergoing Radical Cystectomy”. There is a lack of research on women's quality of life, specifically, on the effect of radical cystectomy on...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Arjun Balar, MD highlights a multicenter study first designed in 2014 of gemcitabine hypofractionated radiation therapy and pembrolizumab all in combination as bladder-sparing therapy for patients with muscle-invasive bladder cancer that had a total of 54 patients. The goal of the study was to test the role of immunotherapy pembrolizumab added to...
|
- Details
- With the oncological safety of TURBT unknown, staging inaccuracies are commonplace, and correct treatment of muscle-invasive bladder cancer is potentially delayed. The BladderPath study is looking at using a multiparametric magnetic resonance imaging (mpMRI) scan to diagnose bladder cancer that has grown into the muscle. Drs. Jim Catto and Gary Steinberg join Dr. Ashish Kamat in a discussion about...
|
- Details
- Yair Lotan joins Ashish Kamat in a slide presentation discussion on urine markers for hematuria and bladder cancer. Dr. Lotan overviews a number of recently published papers and new studies in this space. He highlights limitations and challenges with cytology, the current role of markers and where they stand in clinical use, and urinary markers that are available as well as in development for pati...
|
- Details
- Subtypes in non-muscle-invasive bladder cancer are not well-defined, whereas the molecular landscape of muscle-invasive bladder cancer is relatively well-established. During the optimizing personalized management of non-muscle-invasive bladder cancer session at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Eugene Pietzak, MD, discussed the molecular landscape...
|
- Details
- In this conversation with Ashish Kamat, Lars Dyrskjøt, an expert in the field of molecular markers and personalized medicine speaks about circulating tumor DNA and the potential as a tumor for guiding treatment decisions in bladder cancer. Cell-free DNA in the blood has a half-life of less than two hours, so it makes it possible to use it as a biomarker of the direct tumor burden and hence the det...
|
- Details
- Bernard Bochner joins Ashish Kamat in this discussion discussing the advancements throughout 2020 in muscle-invasive non-metastatic bladder cancer. It would be impossible to discuss the year without mentioning the impact of COVID-19. There are some diseases that can withstand treatment delay, but muscle-invasive bladder cancer is not one of those tumors. These challenges pushed the bladder cancer...
|
- Details
- The European Association of Urology (EAU) published its updated guideline recommendations for non-muscle invasive bladder cancer (NMIBC) in 2020. The updated EAU Guidelines stratify NMIBC into low, intermediate, and high risk for treatment options. In this conversations with Ashish Kamat, MD, MBBS, Marko Babjuk, MD, Ph.D., overviews the 2020 updated guidelines highlighting changes in the guideline...
|
- Details
- Alexander Wyatt from the University of British Columbia joins Ashish Kamat in a discussion on the genomic correlates of Bacillus Calmette-Guerin (BCG) responsive and relapsed non-muscle invasive bladder cancer. Dr. Wyatt shares recent study findings exploring links between common genomic driver alternations and BCG unresponsiveness and also data looking at genomic variables in the context of initi...
|
- Details
- In this conversation with Ashish Kamat, MD, Arjun Balar, MD, MBBS, discusses testing the concept of effectively treating bladder cancer without needing chemotherapy in the non-muscle-invasive disease space, specifically patients with high-risk carcinoma in situ, with or without papillary tumors that had become unresponsive to Bacillus Calmette-Guerin (BCG) based on the current Federal Drug Adminis...
|
